MARLBOROUGH, Mass., Nov. 19, 2026 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (NYSE: BSX) announced today that it has priced a public offering of $3,000,000,000 aggregate principal amount of U.S. dollar-denominated notes (the "USD Offering"), consisting of $1,000,000,000 aggregate principal amount of 5.375% Senior Notes due 2029, $750,000,000 aggregate principal amount of 5.500% Senior Notes due 2031, $750,000,000 aggregate principal amount of 5.750% Senior Notes due 2033 and $500,000,000 aggregate principal amount of 5.875% Senior Notes due 2036 (collectively, the "USD Notes").
Boston Scientific faces rising financing risks as high debt, margin pressures, weaker cash flow expectations and acquisition commitments threaten its financial flexibility.
NEW YORK, Nov. 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
AlTi Global Inc. decreased its position in Boston Scientific Corporation (NYSE: BSX) by 76.0% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 5,109 shares of the medical equipment provider's stock after selling 16,135 shares during the quarter. AlTi Global Inc.'s holdings in
Boston Scientific BSX saw modest sales growth in the third quarter, with revenues climbing 1.5% year over year to $5.14 billion, though its adjusted earnings per share (“EPS”) dipped 2.7% to 73 cents year over year. Primarily due to unexpected headwinds within two high-growth franchises, WATCHMAN and Electrophysiology (“EP”), the company lowered its expectations for the rest of the year.
Aberdeen Group plc increased its position in shares of Boston Scientific Corporation (NYSE: BSX) by 3.5% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,175,308 shares of the medical equipment provider's stock after acquiring an additional 108,682 shares during the period.
Boston Scientific (NYSE: BSX) executives said they expect durable growth across the company's interventional portfolio, while acknowledging that its pulsed field ablation and WATCHMAN businesses face competitive challenges through 2027. Lance Bates, executive vice president and president of interventional cardiology and vascular therapies, said the company's breadth of products and planned launches support an aspiration for
I last wrote about Boston Scientific ( BSX ) as the Bear of the Day in early August after their Q2 report and management's lowered guidance propelled analysts to notch down their EPS estimates for this year and next, causing BSX shares to fall into the cellar of the Zacks Rank.
Allspring Global Investments Holdings LLC cut its position in shares of Boston Scientific Corporation (NYSE: BSX) by 11.4% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 562,224 shares of the medical equipment provider's stock after selling 72,575 shares during the quarter.